Evidence map›Paper›PMID 20174677›Full record

ReviewMolecular bioSystems2010

When ribosomes go bad: diseases of ribosome biogenesis.

Emily F Freed, Franziska Bleichert, Laura M Dutca, Susan J Baserga

Abstract readReview
In one paragraph

Review in Molecular bioSystems, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

103 citing papers in PubMed.

  1. Systematic analysis of noncanonical ribosomal protein paralogs does not provide evidence for specialized functions inProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Targeting cancer via ribosome biogenesis: the cachexia perspective.Cellular and molecular life sciences : CMLS · 2021
    Review
  18. Article
  19. Article
  20. CRL4Science advances · 2020
    Article

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Emily F FreedDepartment of Genetics, Yale University School of Medicine, New Haven, CT 06520, USA.
Franziska Bleichert
Laura M Dutca
Susan J Baserga

Funding

GENETICS AND GENOMICS OF HUMAN DISEASET32HD007149 · NICHD · YALE UNIVERSITY · PI James P Noonan · 1985 to 2026
$8.2M
The Architecture and Function of RNPs Required for Ribosome BiogenesisR01GM052581 · NIGMS · YALE UNIVERSITY · PI BASERGA, SUSAN J · 2001 to 2013
$4.4M
ASSEMBLY, LOCALIZATION AND FUNCTION OF THE U3 SNRNPR29GM052581 · NIGMS · YALE UNIVERSITY · PI BASERGA, SUSAN J · 1996 to 2000
$120k
NICHD NIH HHS 5 T32 HD07149-32NICHD NIH HHS T32 HD007149NIGMS NIH HHS R01 GM052581NIGMS NIH HHS R01GM52581PHS HHS P30-34989
6 · The paper itself

Abstract

Ribosomes are vital for cell growth and survival. Until recently, it was believed that mutations in ribosomes or ribosome biogenesis factors would be lethal, due to the essential nature of these complexes. However, in the last few decades, a number of diseases of ribosome biogenesis have been discovered. It remains a challenge in the field to elucidate the molecular mechanisms underlying them.

Indexed as

MutationDiseaseGenetic Diseases, InbornHumansNeoplasmsRibosomal ProteinsRibosomesRNA PrecursorsRibosomal ProteinsRNA Precursors

Identifiers

PMID20174677
PMCPMC2965583

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.